Germany Exhibition Health (000813): 100 Million Yuan To Set Up Joint Venture Industrial Hemp Layout Next City

After 1 months, de exhibition health (000813) has new actions in the field of industrial hemp.

In the evening of April 8th, the German exhibition Health announced that the company intends to jointly invest with Han Yi biology and natural person Miu Huanhui to set up Han de Pharmaceutical Company Limited. The registered capital is tentatively set at 100 million yuan, and the registered place is tentatively designated as Kunming, Yunnan.

Tak Health said that the establishment of a joint venture is to speed up the company's layout in the field of industrial hemp application, carry out research on cannabinoid compounds, and promote the use of CBD (hemp two phenol) in the treatment of rare diseases and cancer, and other serious diseases that seriously affect human health.

The investment contract shows that German development health contributes to 49% of the registered capital by money, and Han Yi biologically invested 45% of its registered capital with its legally acquired know-how. Miu Huanhui contributed 6% of the registered capital in currency.

The health of Germany exhibition indicates three risks.

In terms of macro risk, although the development of cannabis health industry is developing rapidly, if the macro-economic situation of the country fluctuates greatly, it will inevitably affect the development of the whole industry, thereby adversely affecting the operation of the company.

In terms of market competition risk, more and more enterprises are now entering the field of industrial hemp. With more participants joining, the industry of cannabis industry in the future will face fierce market competition, which may bring uncertainty to the future business of the company.

In addition, there are strict regulations for the cultivation and application of industrial hemp. The cannabis cultivation and processing need to be approved in advance and licensed accordingly.

If the future state policy restricts or prohibits the cultivation and processing of industrial hemp, it may bring greater uncertainty to the business.

It is worth mentioning that, in March 8th, 1 months ago, the German exhibition Health announced that the company signed a framework agreement on equity purchase and comprehensive strategic cooperation with Han Zhong Business Management Group Co., Ltd. and hemp Investment Group Co., Ltd.

The German exhibition health will invest 400 million yuan to obtain the 25% share pledge of Han Ma investment company held by Han Zhong Group.

Germany's health shows that bilateral cooperation is conducive to the layout of the industrial hemp industry chain, opening up the field of biopharmaceutical industry, enriching the product pipeline and enhancing the overall competitiveness.